May 28, 2019American Journal of HypertensionOpen Access

Developments in the Role of Endothelin-1 in Atherosclerosis: A Potential Therapeutic Target?

View Full Paper

Ask AI

Bookmark

Structured PICO

Population

Preclinical models including apolipoprotein-E knockout (ApoE-/-) mice fed a high-fat diet, human umbilical vein endothelial cells (HUVECs), and macrophages

Intervention

Endothelin-1 (ET-1) overexpression and oxidized LDL (oxLDL) exposure

Comparator

Relevant controls (without ET-1 overexpression or oxLDL)

Outcome

Atherosclerotic plaque size and inflammatory macrophage phenotypesurrogate

Limitations

Authors did not treat mice with ET receptor blockers to dissect ETA/ETB signaling
No assessment of vascular function (e.g., using wire myography)
Findings may be restricted to the specific cell lines used (HUVECs expressing greater ETA than ETB)
Lack of investigation of combined ETA/B receptor antagonism

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Endothelin-1 and oxidized LDL synergistically promote macrophage-driven inflammation and atherosclerosis progression in preclinical models, highlighting the ET system as a potential therapeutic target.

Cite This Study

Sutton et al. (2019) studied this question.

synapsesocial.com/papers/6a72d6ca46181537815438f9 https://doi.org/10.1093/ajh/hpz091

View Full Paper

Ask AI

Bookmark

Developments in the Role of Endothelin-1 in Atherosclerosis: A Potential Therapeutic Target?

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Developments in the Role of Endothelin-1 in Atherosclerosis: A Potential Therapeutic Target?

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider